Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBerate-HR: Lerodalcibep in Patients with CVD or High Risk
NCT04806893Phase 3Active, not recruiting
- Sponsor
- LIB Therapeutics
- Start
- Apr 2021
- Primary completion
- Nov 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 3
01
Overview
A Phase 3 trial of lerodalcibep in hypercholesterolemia, cardiovascular disease (CVD), sponsored by LIB Therapeutics. Started Apr 2021; status: active, not recruiting.
02
Drugs
lerodalcibep
03
Conditions
hypercholesterolemiacardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT04806893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04806893.